Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · August 01, 2024

Brigatinib for ROS1 Fusion–Positive NSCLC

ESMO Open

 

Additional Info

ESMO Open
Phase II study of brigatinib in patients with ROS1 fusion-positive non-small-cell lung cancer: the Barossa study
ESMO Open 2024 Jul 16;9(8)103642, S Niho, Y Goto, R Toyozawa, H Daga, K Ohashi, T Takahashi, H Tanaka, J Sakakibara-Konishi, Y Hattori, M Morise, M Kodani, T Ikeda, H Izumi, S Matsumoto, K Yoh, S Nomura, K Goto

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading